Tenax Therapeutics Inc (TENX)
Tenax Therapeutics, Inc. is a development-stage pharmaceutical company focused on cardiopulmonary therapies in the United States. The company is advancing several product candidates, including TNX-101, TNX-102, and TNX-103 (levosimendan), which have completed phase II clinical trials for patients with pulmonary hypertension in heart failure with preserved ejection fraction and related pulmonary hypertension. Its pipeline also includes TNX-201 (imatinib), a tyrosine kinase inhibitor being developed for chronic myeloid leukemia. Tenax Therapeutics trades as common stock on the NASDAQ under the symbol TENX. The company was founded in 1967 and is headquartered in Chapel Hill, North Carolina. It previously operated under the name Oxygen Biotherapeutics, Inc. before adopting its current name in September 2014.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TENX
|
$9.78
|
-37.7% Downside
|
Overvalued
|
$34.75
|
121.3% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 18, 2026
|
-13.9x
|
7.0x
|
—
|
801.1 M
|
684.4 M
|
0.0%
|
51.8%
|
51.8
|
—
|
65.9%
|
